Abstract
For more than 35 years, growth hormone (GH) has been used to promote linear growth in GH-deficient children. Previously, GH replacement in adults was limited to the supply of human pituitary-derived GH. In addition, until recently, GH replacement was not deemed clinically indicated. With the introduction of recombinant human prion-free GH, replacement therapy in GH-deficient adults has become feasible, and its use has burgeoned. In this review, recent studies on GH therapy in healthy and GH-deficient adults are evaluated to provide a rational basis for the widened scope of its clinical application.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
